Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
卡莫司他甲磺酸盐与洛匹那韦/利托那韦治疗 COVID-19 住院患者的疗效比较——一项随机、对照、开放标签平台试验的结果 (ACOVACT)
期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2022.870493
Karolyi, M; Pawelka, E; Omid, S; Koenig, F; Kauer, V; Rumpf, B; Hoepler, W; Kuran, A; Laferl, H; Seitz, T; Traugott, M; Rathkolb, V; Mueller, M; Abrahamowicz, A; Schoergenhofer, C; Hecking, M; Assinger, A; Wenisch, C; Zeitlinger, M; Jilma, B; Zoufaly, A